BCIQ Profiles

Company Profile Report
0414 Future of FerGene

Regulation

Downsized FerGene gains FDA extension to resubmit gene therapy, resolve CMC issues

Investors in the biotech remain committed to the project

A year after the Blackstone-backed Ferring unit received a complete response letter for its gene therapy for bladder cancer, investors in the biotech remain committed to the project.

Apr 15, 2021 | 12:58 AM GMT

Read the full 579 word article

How to gain access

Continue reading with a
two-week free trial.